Dr. Santosh Kesari Joins United Cannabis Corp. Advisory Board
October 10 2017 - 8:30AM
Access Wire
Renowned Neuro-Oncologist Will Work with Company to
Develop Protocols for the Treatment of Brain
Tumors
DENVER, CO / ACCESSWIRE / October 10, 2017 /
United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United
Cannabis") today announced that Dr. Santosh Kesari has joined the
Company's Advisory Board. Ranked among the top 1% of
neuro-oncologists and neurologists in the nation, Dr. Kesari will
work with the Company to develop clinical trial protocols to study
the effects of Prana on cancers.
Dr. Kesari has had a long-standing interest in cancer stem cells
and studies their role in the formation of brain tumors and
resistance to treatment. He is a board-certified neurologist and
neuro-oncologist and is currently Chair and Professor, Department
of Translational Neurosciences and Neurotherapeutics, John Wayne
Cancer Institute. He is also Director of Neuro-oncology, Providence
Saint John's Health Center and leads the Pacific Neuroscience
Research Center at Pacific Neuroscience Institute.
He is a winner of an Innovation Award by the San Diego Business
Journal. He is on the advisory board of American Brain Tumor
Association, San Diego Brain Tumor Foundation, Chris Elliott Fund,
Nicolas Conor Institute, Voices Against Brain Cancer, and
Philippine Brain Tumor Alliance. He has been the author of over 250
scientific publications, reviews, or books. He is the inventor on
several patents and patent applications, and founder and advisor to
many cancer and neurosciences focused biotech startups. In
addition, he is a member of the Los Angeles Biomedical Research
Institute.
Earnest Blackmon, Chief Executive Officer of United Cannabis,
commented on the announcement, "Dr. Kesari is an internationally
recognized scientist and clinician, and we are honored that he has
agreed to share his knowledge and expertise to help us advance our
clinical programs focused on cancer care and brain health."
Commenting on the appointment, Dr. Kesari added, "There is a
growing body of pre-clinical evidence that drugs developed from
natural products can have a profound impact on tumor cell behavior
and improving overall survival in a number of cancer subtypes.
Similarly, plant-based therapeutics can play a role in supporting
brain health and repair. United Cannabis' research program in these
two areas is unique and has the potential to make an impact in both
of these areas. I am looking forward to working with their research
team and providing help as these programs move into the
clinic."
About United Cannabis Corporation
United Cannabis is a biotechnology company dedicated to the
development of phyto-therapeutic based products supported by
patented technologies for the pharmaceutical, medical, and
industrial markets. Our products include supplements, medical
cannabis therapeutics and pharmaceutical drugs.
For further information, please visit www.unitedcannabis.us.
Contact: Staff@UnitedCannabis.us
Phone: 303-386-7321
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933, are subject to Rule 3b-6 under the
Securities Exchange Act of 1934, and are subject to the safe
harbors created by those rules. All statements, other than
statements of fact, included in this release, including, without
limitation, statements regarding potential future plans and
objectives of the company, are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and other results and
further events could differ materially from those anticipated in
such statements. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements.
SOURCE: United Cannabis Corporation